摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Marsanidine | 1034875-38-1

中文名称
——
中文别名
——
英文名称
Marsanidine
英文别名
1-[(imidazolidin-2-yl)imino]indazole;N-(4,5-dihydro-1H-imidazol-2-yl)indazol-1-amine
Marsanidine化学式
CAS
1034875-38-1
化学式
C10H11N5
mdl
——
分子量
201.231
InChiKey
PFTFJTOQCWYCNM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    54.2
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    Marsanidine盐酸 作用下, 以 甲醇 为溶剂, 以75%的产率得到1-[(imidazolidin-2-yl)imino]indazole hydrochloride
    参考文献:
    名称:
    [EN] DERIVATIVES OF 1-[(IMIDAZOLIDIN-2-YL)IMINO)]INDAZOLE
    [FR] DÉRIVÉS DU 1-[(IMIDAZOLIDIN-2-YL)IMINO)]INDAZOLE
    摘要:
    本发明提供了一种式子为(I)的化合物,其中R1表示氢、甲基或苯基;R2、R3、R4和R5表示氢、卤素,优选为氯原子,烷基,优选为甲基,烷氧基,优选为甲氧基;m表示数字0或1;HX表示硫酸、磷酸、醋酸、马龙酸、富马酸、草酸、乳酸、酒石酸、柠檬酸、葡萄糖酸、对甲苯磺酸、甲磺酸、氢溴酸或氢碘酸,优选为氢氯酸。本发明还提供将该化合物用作α2肾上腺素受体激动剂的方法。
    公开号:
    WO2009071906A1
  • 作为产物:
    描述:
    1-{[1,3-di(tert-butoxycarbonyl)imidazolidin-2-yl]imino}indazole 在 三氟乙酸 、 sodium hydroxide 作用下, 以 二氯甲烷 为溶剂, 反应 2.0h, 以60%的产率得到Marsanidine
    参考文献:
    名称:
    [EN] DERIVATIVES OF 1-[(IMIDAZOLIDIN-2-YL)IMINO)]INDAZOLE
    [FR] DÉRIVÉS DU 1-[(IMIDAZOLIDIN-2-YL)IMINO)]INDAZOLE
    摘要:
    本发明提供了一种式子为(I)的化合物,其中R1表示氢、甲基或苯基;R2、R3、R4和R5表示氢、卤素,优选为氯原子,烷基,优选为甲基,烷氧基,优选为甲氧基;m表示数字0或1;HX表示硫酸、磷酸、醋酸、马龙酸、富马酸、草酸、乳酸、酒石酸、柠檬酸、葡萄糖酸、对甲苯磺酸、甲磺酸、氢溴酸或氢碘酸,优选为氢氯酸。本发明还提供将该化合物用作α2肾上腺素受体激动剂的方法。
    公开号:
    WO2009071906A1
点击查看最新优质反应信息

文献信息

  • [EN] IMIDAZOLINE RECEPTOR TYPE 1 LIGANDS FOR USE AS THERAPEUTICS<br/>[FR] LIGANDS DU RÉCEPTEUR AUX IMIDAZOLINES DE TYPE 1 À UTILISER EN TANT QU'AGENTS THÉRAPEUTIQUES
    申请人:RIDEOUT DARRYL
    公开号:WO2016105448A1
    公开(公告)日:2016-06-30
    This disclosure provides compounds and compositions for use as analgesics and for the treatment of various conditions, such as pain, headaches, allodynia, and fibromyalgia. The disclosure also provides compounds that are ligands, and in some embodiments, modulators (e.g., agonists), for the imidazoline receptor type 1.
    本公开提供了作为止痛剂和用于治疗各种病症的化合物和组合物,如疼痛、头痛、触痛和纤维肌痛。本公开还提供了作为嘌呤受体1的配体的化合物,有些实施例中还提供了对其的调节剂(例如,激动剂)。
  • [EN] COMPOUNDS FOR USE AS PAIN THERAPEUTICS<br/>[FR] COMPOSÉS DESTINÉS À ÊTRE UTILISÉS EN TANT QU'AGENTS THÉRAPEUTIQUES CONTRE LA DOULEUR
    申请人:LEDERMAN SETH
    公开号:WO2016105449A1
    公开(公告)日:2016-06-30
    This disclosure provides compounds and compositions for use as analgesics and for the treatment of one or more conditions selected from: pain; psychic pain; psychological pain; psychiatric pain; depression; allodynia; fibromyalgia; fibromyalgia-ness; central sensitization; centralization; regional pain syndrome; temporomandibular joint syndrome (TMJ); lower back pain; interstitial cystitis; Gulf War syndrome; visceral pain; phantom limb painj.kidney stones; gout; neuropathic pain; post-herpetic neuralgia; diabetic neuropathy; sickle cell pain; priapism; nociceptive pain; post-operative pain; orthopedic injury pain; bunionectomy; dental extraction; pain after severed spinal cord injury; osteoarthritis; rheumatoid arthritis; Lyme disease; Parkinson's disease; opioid-induced constipation; an opioid withdrawal symptom; pain associated with post-traumatic stress disorder (PTSD); and combinations of any of the foregoing conditions. This disclosure also provides compounds that are ligands, and in some embodiments, modulators (e.g., agonists), for the imidazoline receptor type 1.
    本公开提供了用作镇痛剂和用于治疗以下一种或多种疾病的化合物和组合物:疼痛;心理疼痛;心理疼痛;精神疼痛;抑郁症;痛觉过敏;纤维肌痛;纤维肌痛症;中枢敏感化;中枢化;区域性疼痛综合征;颞下颌关节综合征(TMJ);腰部疼痛;间质性膀胱炎;海湾战争综合征;内脏疼痛;幻肢疼痛;肾结石;痛风;神经性疼痛;带状疱疹后神经痛;糖尿病性神经病;镰状细胞疼痛;阴茎长时间勃起症;伤害性疼痛;术后疼痛;骨科损伤疼痛;拇外翻术;牙科拔牙;断裂脊髓损伤后疼痛;骨关节炎;类风湿关节炎;莱姆病;帕金森病;阿片类药物引起的便秘;阿片类药物戒断症状;与创伤后应激障碍(PTSD)相关的疼痛;以及上述任何疾病的组合。本公开还提供了作为咪唑啉受体类型1的配体的化合物,有些实施例中是调节剂(例如,激动剂)。
  • [EN] DERIVATIVES OF 1-[(IMIDAZOLIDIN-2-YL)IMINO)]INDAZOLE<br/>[FR] DÉRIVÉS DU 1-[(IMIDAZOLIDIN-2-YL)IMINO)]INDAZOLE
    申请人:IMP INNOVATIONS LTD
    公开号:WO2009071906A1
    公开(公告)日:2009-06-11
    The invention provides a compound of formula (I) wherein R1 denotes hydrogen, methyl or phenyl; R2, R3, R4 and R5 denote hydrogen, halogen, preferably a chlorine atom, alkyl, preferably methyl, alkoxyl, preferably methoxyl; m denotes a number 0 or 1; and HX denotes sulfuric, phosphoric, acetic, malonic, fumaric, oxalic, lactic, tartaric, citric, gluconic, p-toluenesulfonic, methanesulfonic acid, hydrogen bromide or hydrogen iodide, preferably hydrogen chloride. The use of the compounds as α2-adrenergic receptor agonists is also provided.
    本发明提供了一种式子为(I)的化合物,其中R1表示氢、甲基或苯基;R2、R3、R4和R5表示氢、卤素,优选为氯原子,烷基,优选为甲基,烷氧基,优选为甲氧基;m表示数字0或1;HX表示硫酸、磷酸、醋酸、马龙酸、富马酸、草酸、乳酸、酒石酸、柠檬酸、葡萄糖酸、对甲苯磺酸、甲磺酸、氢溴酸或氢碘酸,优选为氢氯酸。本发明还提供将该化合物用作α2肾上腺素受体激动剂的方法。
  • Fluorinated analogues of marsanidine, a highly α2-AR/imidazoline I1 binding site-selective hypotensive agent. Synthesis and biological activities
    作者:Aleksandra Wasilewska、Franciszek Sączewski、Alan L. Hudson、Mehnaz Ferdousi、Mika Scheinin、Jonne M. Laurila、Apolonia Rybczyńska、Konrad Boblewski、Artur Lehmann
    DOI:10.1016/j.ejmech.2014.09.083
    日期:2014.11
    The aim of these studies was to establish the influence of fluorination of the indazole ring on the pharmacological properties of two selective alpha(2)-aradrenoceptor (alpha(2)-AR) agonists: 1-[(imidazolidin-2-yl) imino]-1H-indazole (marsanidine, A) and its methylene analogue 1-[(4,5-dihydro-1H-imidazol-2-yl) methyl]-1H-indazole (B). Introduction of fluorine into the indazole ring of A and B reduced both binding affinity and alpha(2)-AR/I-1 imidazoline binding site selectivity. The most alpha(2)-AR-selective ligands were 6-fluoro-1-[(imidazolidin-2-yl)imino]-1H-indazole (6c) and 7-fluoro-1-[(imidazolidin-2-yl)imino]-1H-indazole (6d). The in vivo cardiovascular properties of fluorinated derivatives of A and B revealed that in both cases the C-7 fluorination leads to compounds with the highest hypotensive and bradycardic activities. The alpha(2)-AR partial agonist 6c was prepared as a potential lead compound for development of a radiotracer for PET imaging of brain alpha(2)-ARs. (C) 2014 Elsevier Masson SAS. All rights reserved.
  • 2-IMIDAZOLINYLAMINOINDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS
    申请人:THE PROCTER & GAMBLE COMPANY
    公开号:EP0944620A1
    公开(公告)日:1999-09-29
查看更多